Pharmaceuticals News and Research

RSS

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

Tibet Pharmaceuticals' updated online Investor Fact Sheet is now available in China

Tibet Pharmaceuticals, Inc., an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, announces the availability of an updated online Investor Fact Sheet.

18 Apr 2011

Idera's gene-silencing oligonucleotide studies published in Journal of Medicinal Chemistry

Idera Pharmaceuticals, Inc. today announced the online publication in the Journal of Medicinal Chemistry of its studies of a novel class of compounds, which we refer to as gene-silencing oligonucleotides.

18 Apr 2011

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

18 Apr 2011

FDA accepts Regeneron's VEGF Trap-Eye BLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company's Biologics License Application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.

18 Apr 2011

iOWH's semisynthetic ART enters production, distribution phase to combat malaria

The Institute for OneWorld Health, a non-profit drug development organization, announced today that its development of an alternative source of artemisinin using pioneering synthetic biology technology has successfully entered the production and distribution phase.

18 Apr 2011

Nuvo Research to acquire ZARS Pharma

Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.

18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Scientists develop new compound for multiple sclerosis treatment

Scientists from the Florida campus of The Scripps Research Institute have developed the first of a new class of highly selective compounds that effectively suppresses the severity of multiple sclerosis in animal models.

18 Apr 2011

Pharmatek receives U.S. DEA approval for Schedule I-V controlled substance analysis

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has been approved by the United States Drug Enforcement Agency for the analysis of Schedules I through V controlled substances, complementing its existing license to develop and manufacture drug products containing Schedules IV and V controlled substances.

18 Apr 2011

Thermo Fisher Scientific introduces wireless sample monitoring solution

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced its new Thermo Scientific Smart-Vue wireless monitoring solution. Smart-Vue™ protects precious samples by monitoring key laboratory parameters including temperature, CO2 concentration, humidity and differential pressure. It can be installed by the user on most laboratory equipment, including ultra-low temperature freezers, laboratory refrigerators, CO2 incubators and clean rooms.

From Thermo Fisher Scientific Inc. 16 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering Par Pharmaceutical Inc. not to make, use, sell, offer to sell, or import into the United States a generic version of sumatriptan/naproxen sodium that competes with Treximet sold by GlaxoSmithKline in the United States under an exclusive license from the Company.

15 Apr 2011

Merck begins tender offer for all Inspire shares

Merck, known as MSD outside the United States and Canada, today announced the commencement of the tender offer for all outstanding shares of Inspire Pharmaceuticals, Inc. for $5.00 per share in cash without interest and less any applicable withholding taxes.

15 Apr 2011

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Johnson & Johnson (NYSE: JNJ) and its subsidiary Centocor Ortho Biotech Inc., today announced that the companies have reached agreement to amend the distribution rights to REMICADE and SIMPONI, which treat chronic inflammatory diseases such as rheumatoid arthritis.

15 Apr 2011

RXi prices underwritten public offering of 11,950,000 shares of common stock

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using immunotherapy and RNA-targeted technologies, today announced that it has priced an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12 million.

15 Apr 2011

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.

15 Apr 2011

AMGA honors Boehringer Ingelheim with Distinguished Corporate Partner Award

The American Medical Group Association announced today that it will present the AMGA Distinguished Corporate Partner Award on April 16 to Boehringer Ingelheim Pharmaceuticals at its 2011 Annual Conference, April 13-16 at the Gaylord National.

15 Apr 2011

African genital herpes strains are more infectious than the U.S. virus

Strains of genital herpes in Africa are far more virulent than those in the United States, researchers at Harvard Medical School report, a striking insight into a common disease with important implications for preventing HIV transmission in a region staggered by the HIV/AIDS epidemic.

15 Apr 2011